BrightPath Biotherapeutics Co., Ltd. Stock price

Equities

4594

JP3274140007

Biotechnology & Medical Research

Delayed Japan Exchange 02:00:00 2024-03-29 am EDT 5-day change 1st Jan Change
67 JPY +4.69% Intraday chart for BrightPath Biotherapeutics Co., Ltd. +1.52% -22.99%
Sales 2017 529M 3.49M Sales 2018 354M 2.34M Capitalization 33.68B 222M
Net income 2017 -1.11B -7.35M Net income 2018 -1.58B -10.42M EV / Sales 2017 34.8 x
Net cash position 2017 4.95B 32.69M Net cash position 2018 6.53B 43.12M EV / Sales 2018 76.7 x
P/E ratio 2017
-19.2 x
P/E ratio 2018
-19.5 x
Employees 42
Yield 2017 *
-
Yield 2018
-
Free-Float 95.5%
More Fundamentals * Assessed data
Dynamic Chart
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited CI
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index CI
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine MT
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment MT
Brightpath Biotherapeutics Announces Preclinical Data on BP1209 CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019 CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018 CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019 CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018 CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm CI
More news
1 day+4.69%
1 week+1.52%
Current month-16.25%
1 month-16.25%
3 months-22.99%
6 months-50.74%
Current year-22.99%
More quotes
1 week
63.00
Extreme 63
68.00
1 month
63.00
Extreme 63
90.00
Current year
63.00
Extreme 63
99.00
1 year
63.00
Extreme 63
185.00
3 years
61.00
Extreme 61
270.00
5 years
61.00
Extreme 61
389.00
10 years
61.00
Extreme 61
2 229.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 08-12-31
Director/Board Member 55 16-04-30
Members of the board TitleAgeSince
Director/Board Member 77 15-05-31
Director/Board Member 67 03-04-30
Chief Executive Officer 53 08-12-31
More insiders
Date Price Change Volume
24-03-29 67 +4.69% 388 900
24-03-28 64 0.00% 608,800
24-03-27 64 -1.54% 718,900
24-03-26 65 -1.52% 847,900
24-03-25 66 0.00% 473,800

Delayed Quote Japan Exchange, March 29, 2024 at 02:00 am EDT

More quotes
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.
More about the company
  1. Stock
  2. Equities
  3. Stock BrightPath Biotherapeutics Co., Ltd. - Japan Exchange